Results 1 to 10 of about 1,769 (97)

Quantitative and qualitative evaluation of the use of nonsteroidal anti-inflammatory drugs in the Russian Federation over 10 years

Качественная клиническая практика, 2022
Relevance. Studies devoted to the assessment of consumption, as well as to the issues of pharmacosafety of nonsteroidal anti-inflammatory drugs, are limited at the national level in the Russian Federation.
G. I. Syraeva, A. S. Kolbin, S. A. Mishinova, A. A. Kalyapin   +3 more
doaj   +1 more source

Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base

Качественная клиническая практика, 2021
Effective control of Diabetes Mellitus (DM) is an actual task from clinical and economic points of view. The second generation insulin analogs increase level of DM compensation without hypoglycemia. The economic aspects of their usage have been evaluated
I. N. Dyakov, S. K. Zyryanov
doaj   +1 more source

Pharmacoeconomic characteristics of agonists of receptors for glucagon-like peptide-1 and medicines on their base

Качественная клиническая практика, 2021
The effective control of Diabetes Mellitus (DM) is an actual problem from optimal expenditures of health care system point of view. Agonists of receptors for glucagon like peptide-1 (aGLP-1) are one of the modern option for glycemia control in DM Type 2 ...
I. N. Dyakov, S. K. Zyryanov
doaj   +1 more source

Farmakoekonomicheskie aspekty umen'sheniya mikroa11'buminurii u bol'nykh gipertonicheskoy bolezn'yu i sakharnym diabetom tipa 2

Сахарный диабет, 2004
У больных гипертонической болезнью и СД с МА наиболее оправданным с фармакоэкономических позиций является применение индапамида-ретард и эналаприла в дозе, не превышающей 12 мг/сут.
V Petrov, S Nedogoda, A Sabanov
doaj   +1 more source

Farmakoekonomicheskiy analiz ispol'zovaniya intensivnoy taktiki lecheniya bol'nykh sakharnym diabetom 2 tipa

Сахарный диабет, 2004
Цель. Оценка клинических показателей интенсивной инсулинотерапии и комбинированной терапии инсулином и пероральными сахароснижающим препаратами (ПССП) больных СД 2 для достижения целевых значений ...
Olga Mikhailovna Smirnova
doaj   +1 more source

PHARMACOECONOMICS OF APPLICATION OF HEPATOPROTECTORS IN THERAPY OF DRUG-INDUCED LIVER INJURY AFTER CHEMOTHERAPY

Acta Biomedica Scientifica, 2017
One of the major problems of modern oncology drug is liver damage, requiring additional costs for its treatment. The aim of our work was to study medical and economic efficiency of various schemes of hepatoprotective treatment of toxic liver damage.
D. D. Morikov, E. G. Morikova, D. M. Ponomarenko   +2 more
doaj   +1 more source

Pharmacoeconomic evaluation of the ceftolosan + tasobactam in the treatment of complicated nosocomial intraabdominal infections

Качественная клиническая практика, 2019
Objective. To perform the pharmacoeconomic analysis of ceftolosan + tazobactam (Zerbaxa®) compared with the routine practice of antibacterial therapy of complicated intra-abdominal infections (clAI) and ceftazidime + avibactam (Zavicefta®).Methods.
I. N. Dyakov, S. K. Zyryanov, N. N. Khachatryan   +2 more
doaj   +1 more source

Updated guidelines of reporting pharmacoeconomics and health technology assessment results from 2022 ISPOR (CHEERS 2022)

Качественная клиническая практика, 2022
In 2022, ISPOR released an updated checklist on economic evaluation of health care, since the latter several years have passed, the circumstances have changed, and science has progressed that it demanded fresh relevant changes. To support decision-making
M. A. Truuts, A. A. Kurilev, A. S. Kolbin   +2 more
doaj   +1 more source

Determination of the reference value of the incremental cost-efficacy and cost-utility coefficient in Russia in oncology

Качественная клиническая практика, 2018
The share of antineoplastic drug dossiers submitted to reimbursement in Russia raised from 15% in 2014 to 28% in 2017. The effectiveness and safety of innovative anti-cancer therapy is higher comparing to widely used traditional treatments.
A. S. Kolbin, A. A. Kurylev
doaj   +1 more source

An update of pharmacoeconomic analysis of trastuzumab emtanzine in patients with HER2+ breast cancer and central nervous system metastases

Качественная клиническая практика, 2019
Introduction. Regardless the pharmacoeconomic evaluation of trastuzumab emtanzine (T-DM-1) has been done before new data concerning T-DM1 effectiveness and also costs data require an update of pharmacoeconomic evaluation. Aim.
A. S. Kolbin, A. A. Kurylev, Y. E. Balykina, M. A. Proskurin   +3 more
doaj   +1 more source